Skip to main content
IRD
NASDAQ Life Sciences

Wiseek Filing Insight

Analysis by Wiseek.ai•Reviewed by Editorial Team
Sentiment info
Neutral
Importance info
3
Price
$4.992
Mkt Cap
$365.581M
52W Low
$0.754
52W High
$5.81
Market data snapshot near publication time

check_boxKey Events

  • No key events were highlighted for this filing.

auto_awesomeAnalysis

No analysis available.

At the time of this filing, IRD was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $365.6M. The 52-week trading range was $0.75 to $5.81. This filing was assessed with an importance score of 3 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed IRD - Latest Insights

IRD
Apr 24, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Opus Genetics Secures Initial $35M Funding from Senior Secured Note Agreement
Sentiment: Positive
View Wiseek Article
IRD
Apr 22, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Opus Genetics Stockholders Approve Doubling Authorized Shares to 250 Million
Sentiment: Negative
View Wiseek Article
IRD
Apr 20, 2026, 7:07 PM EDT
Filing Type: S-3/A
Importance Score:
8
Opus Genetics Registers Resale of 7.37M Shares from February Private Placement, Posing Significant Dilution Risk
Sentiment: Negative
View Wiseek Article
IRD
Apr 07, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Opus Genetics Secures Top Executives with Change in Control Tax Protection
Sentiment: Neutral
View Wiseek Article
IRD
Apr 06, 2026, 7:42 PM EDT
Filing Type: 8-K
Importance Score:
8
Opus Genetics Secures Up to $155M in Strategic Financing, Extending Cash Runway to 2029
Sentiment: Positive
View Wiseek Article
IRD
Apr 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Opus Genetics Secures Up To $155M Non-Dilutive Financing, Extends Runway to 2029
Sentiment: Positive
View Wiseek Article
IRD
Mar 13, 2026, 4:56 PM EDT
Filing Type: S-3
Importance Score:
7
Opus Genetics Files S-3 for Resale of $36M in Common Stock by Selling Stockholders
Sentiment: Negative
View Wiseek Article
IRD
Mar 12, 2026, 4:58 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Shareholders to Vote on Doubling Authorized Shares to 250M, Critical for Converting Recent $25M Preferred Stock Financing
Sentiment: Neutral
View Wiseek Article
IRD
Mar 12, 2026, 4:52 PM EDT
Filing Type: 10-K
Importance Score:
8
Opus Genetics Details Strong Pipeline Progress, Key Regulatory Milestones, and Strengthened Liquidity in Annual Report
Sentiment: Positive
View Wiseek Article
IRD
Mar 10, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Opus Genetics Reports FY25 Results, Extends Cash Runway to 2028, and Secures October 2026 FDA PDUFA Date
Sentiment: Positive
View Wiseek Article